Joint Corp (NASDAQ:JYNT) fell 4.8% during mid-day trading on Wednesday . The stock traded as low as $2.00 and last traded at $2.00, with a volume of 81,592 shares traded. The stock had previously closed at $2.10.

Several brokerages have issued reports on JYNT. Maxim Group lowered their price target on Joint Corp from $8.00 to $5.00 and set a “buy” rating for the company in a report on Friday, July 1st. Feltl & Co. downgraded Joint Corp from a “strong-buy” rating to a “buy” rating in a report on Friday, June 24th. Finally, Zacks Investment Research upgraded Joint Corp from a “sell” rating to a “hold” rating in a report on Tuesday, May 17th.

The company has a 50-day moving average price of $2.77 and a 200-day moving average price of $3.73. The company’s market cap is $24.20 million.

Joint Corp (NASDAQ:JYNT) last released its earnings results on Thursday, May 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.02. The business earned $4.30 million during the quarter, compared to the consensus estimate of $4.52 million. Equities research analysts forecast that Joint Corp will post ($1.01) earnings per share for the current year.

In other Joint Corp news, major shareholder Glenhill Advisors Llc bought 80,069 shares of Joint Corp stock in a transaction dated Friday, July 1st. The stock was bought at an average cost of $1.97 per share, with a total value of $157,735.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.